Stratum Nutrition and Clasado Biosciences have announced a new distribution agreement for the multi-award-winning prebiotic galactooligosaccharide ingredient, Bimuno GOS
UK-based Clasado Biosciences, an international biotechnology company that develops advanced prebiotic solutions for food, supplement and healthcare companies across the global wellness market, has announced a brand-new distribution agreement with dietary supplement ingredient distributor, Stratum Nutrition.
The agreement gives Stratum exclusive rights to distribute the multi-award-winning prebiotic galactooligosaccharide ingredient, Bimuno GOS, to the USA and Canadian markets, providing a robust distribution channel for functional foods and beverages as well as health and nutrition brands.
With consumer interest in prebiotics accelerating at pace across North America, the future of health and nutrition formulation is an exciting area for microbiome-modulating products
Dr Frederic Narbel, VP of B2B Sales at Clasado, said: “As gut microbiome health awareness continues to accelerate, we are delighted to announce our exclusive distribution deal with Stratum. Prebiotics are climbing the consumer agenda, with a global compound annual growth rate (CAGR) of almost 15%*. With consumer interest in prebiotics accelerating at pace across North America, the future of health and nutrition formulation is an exciting area for microbiome-modulating products.
Narbel continued: “With a focus on unique ingredients combined with their outstanding technical and market expertise, Stratum is an ideal partner to supply our prebiotic ingredient. Bimuno GOS stands apart from alternatives through the scientific studies behind it, which forms one of the most comprehensive portfolios on the market as well as approved health claims in select territories. Versatile, stable and rooted in scientific research, it’s never been easier to formulate the next generation of health and nutrition supplements!”
The most studied ingredient of its kind, the safety and efficacy of Bimuno GOS is supported by over 100 scientific publications, including more than 20 clinical trials. The ingredient’s unique composition enables it to selectively nourish bifidobacteria, a beneficial bacteria in the gut microbiome, that helps to support numerous health areas such as gastrointestinal, immune and cognitive health. In addition, its strong scientific portfolio enables the use of 25 possible structure and function claims in the USA to help formulators using Bimuno GOS stand out from the crowd.
Extremely stable and resistant to heat and acidity, Bimuno GOS can be added to formulations at any stage of manufacturing and offers one of the most attractively low efficacious dosages on the market, beginning from just 1.37g per day.
Micah Osborne, CEO of Stratum, added: “Today’s health audience is more proactive than ever before. Consumers the world over are getting more attuned to the benefits of better gut health, the importance of the gut microbiome and its role in supporting everyday health. Understanding that beneficial gut bacteria influence non-digestive health in important areas such as immunity and mental health unlocks entirely new paths for product development, and presents a fantastic opportunity to meet rising consumer demand.
“We are in the age of gut health innovation, and the commercial potential of prebiotics is significant," Osborne continued. "Their stability also makes them suitable for a wide range of applications, no longer are they exclusively used in supplements, but increasingly in functional food and beverages. We are pleased to add Bimuno GOS to our ingredient portfolio as it aligns with our scientific values, and we look forward to supporting our customers in formulating their own prebiotic product ranges.”